Immunotherapy for head and neck cancer patients: Shifting the balance

Immunotherapy

Volumn 5, Issue 1, 2013, Pages 49-61

  Turksma, Annelies W ^a   Braakhuis, Boudewijn J ^b   Bloemena, Elisabeth ^a,c   Meijer, Chris J ^a   Leemans, C René ^b   Hooijberg, Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Otolaryngology/Head and Neck Surgery   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

active immunotherapy; head and neck squamous cell carcinoma; HPV; human papilloma virus; immunotherapy; passive immunotherapy; vaccination

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CATUMAXOMAB; CETUXIMAB; CYCLOOXYGENASE 2; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; IRX 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PANITUMUMAB; PROSTAGLANDIN E2; PROTEIN P53; RECOMBINANT ALPHA INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SMAD PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALCOHOL CONSUMPTION; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PASSIVE IMMUNIZATION; PERSISTENT INFECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SMOKING; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR ESCAPE; VIRUS CARCINOGENESIS; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84871571023     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.135     Document Type: Review

References (147)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
2. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of mouth cancer: A review of global incidence. Oral Dis. 6(2), 65-74 (2000).
3. Weijers M, Leemans CR, Aartman IH, Karagozoglu KH, van der Waal I. Oral cancer trends in a single head-and-neck cancer center in the Netherlands; decline in T-stage at the time of admission. Med. Oral Patol. Oral Cir. Bucal. 16(5), e914-e918 (2011).
4. Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol. 45(9), e85-e89 (2009).
5. Brennan JA, Boyle JO, Koch WM et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332(11), 712-717 (1995).
6. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat. Rev. Cancer 11(1), 9-22 (2011).
7. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 118, 510-519 (2010).
8. Klussmann JP, Weissenborn SJ, Wieland U et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92(11), 2875-2884 (2001).
9. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol. Biomarkers Prev. 14(2), 467-475 (2005).
10. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr. Treat. Options Oncol. 13(1), 35-46 (2012).
11. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
12. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst. 100(4), 261-269 (2008).
13. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol. 27(12), 1992-1998 (2009).
14. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2, 15 (2010).
15. Hong AM, Dobbins TA, Lee CS et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br. J. Cancer 103(10), 1510-1517 (2010).
16. Poeta ML, Manola J, Goldwasser MA et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 357(25), 2552-2561 (2007).
17. van Houten V, Tabor MP, van den Brekel MW et al. Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. J. Pathol. 198(4), 476-486 (2002).
18. Reed AL, Califano J, Cairns P et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56(16), 3630-3633 (1996).
19. Uribe P, Gonzalez S. EGF receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy. Pathol. Res. Pract. 207(6), 337-342 (2011).
20. Wang D, Song H, Evans JA, Lang JC, Schuller DE, Weghorst CM. Mutation and downregulation of the transforming growth factor b type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18(11), 2285-2290 (1997).
21. Engelman JA. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
22. Chung CH, Parker JS, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5(5), 489-500 (2004).
23. Smeets SJ, Braakhuis BJ, Abbas S et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25(17), 2558-2564 (2006).
24. Perrone F, Suardi S, Pastore E et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 12(22), 6643-6651 (2006).
25. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: Infection with high-risk vs low-risk human papillomaviruses. APMIS 118(6-7), 471-493 (2010).
26. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci. 13, 1003-1017 (2008).
27. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat. Cell Biol. 2(4), e65-e67 (2000).
28. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells (DC). Nat. Rev. Cancer 12(4), 265-277 (2012).
29. Bear AS, Cruz CR, Foster AE. T cells as vehicles for cancer vaccination. J. Biomed. Biotechnol. 2011, 417403 (2011).
30. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54(8), 721-728 (2005).
31. Yoshimura A, Muto G. Transforming growth factor-b function in immune suppression. Curr. Top. Microbiol. Immunol. 350, 127-147 (2011).
32. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 61, 869-872 (2001).
33. Niu BL, Du HM, Shen HP et al. Myeloid DC loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: A potentially promising tumor vaccine. Vaccine 30(23), 3395-3404 (2012).
34. Chikamatsu K, Albers A, Stanson J et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res. 63(13), 3675-3681 (2003).
35. Saha A, Kaul R, Murakami M, Robertson ES. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention. Cancer Biol. Ther. 10(10), 961-978 (2010).
36. Bajaj BG, Murakami M, Robertson ES. Molecular biology of EBV in relationship to AIDS-associated oncogenesis. Cancer Treat. Res. 133, 141-162 (2007).
37. Thompson MP, Kurzrock R. EpsteinYBarr virus and cancer. Clin. Cancer Res. 10(3), 803-821 (2004).
38. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2), 137-148 (2004).
39. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3(11), 999-1005 (2002).
40. Distel LV, Fickenscher R, Dietel K et al. Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: Prognostic impact may depend on type of treatment and stage of disease. Oral. Oncol. 45(10), e167-e174 (2009).
41. Griffioen AW, Tromp SC, Hillen HF. Angiogenesis modulates the tumour immune response. Int. J. Exp. Pathol. 79(6), 363-368 (1998).
42. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
43. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
44. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92(5), 913-920 (2005).
45. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-10 and transforming growth factor-b1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13(15 Pt 1), 4345-4354 (2007).
46. Muraki Y, Yoshioka C, Tateishi A, Fukuda J, Haneji T, Kobayashi N. Localization of Fas antigen in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg. 37(1), 37-40 (1999).
47. Jackel MC, Mitteldorf C, Schweyer S, Fuzesi L. Clinical relevance of Fas (APO-1/CD95) expression in laryngeal squamous cell carcinoma. Head Neck 23(8), 646-652 (2001).
48. Bayazit Y, Mumbuc S, Ucak R, Kanlikama M, Bakir K. Significance of Fas protein in squamous cell carcinoma of the larynx. Acta Otolaryngol. 120(4), 557-561 (2000).
49. Li X, Pan X, Zhang H et al. Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. J. Cancer Res. Clin. Oncol. 134(5), 609-615 (2008).
50. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 388(6638), 190-195 (1997).
51. Altieri DC. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 3(1), 46-54 (2003).
52. Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 29(9), 874-884 (2007).
53. Rubinstein N, Alvarez M, Zwirner NW et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5(3), 241-251 (2004).
54. Grandis JR, Drenning SD, Chakraborty A et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. 102(7), 1385-1392 (1998).
55. Grandis JR, Drenning SD, Zeng Q et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl Acad. Sci. USA 97(8), 4227-4232 (2000).
56. Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer 94(9), 2393-2400 (2002).
57. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
58. Kijima T, Niwa H, Steinman RA et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 13(8), 355-362 (2002).
59. Scheper MA, Nikitakis NG, Sauk JJ. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int. J. Oral Maxillofac. Surg. 36(7), 632-639 (2007).
60. Albesiano E, Davis M, See AP et al. Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res. 70(16), 6467-6476 (2010).
61. Karin M, Greten FR. NF-kB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5(10), 749-759 (2005).
62. Ondrey FG, Dong G, Sunwoo J et al. Constitutive activation of transcription factors NF-(k)B, activator protein-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol. Carcinog. 26(2), 119-129 (1999).
63. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS. Molecular cross-talk between the NFkB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 8(9), 733-746 (2006).
64. Chan G, Boyle JO, Yang EK et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59(5), 991-994 (1999).
65. Camacho M, Leon X, Fernandez-Figueras MT, Quer M, Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 30(9), 1175-1181 (2008).
66. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 33(7), 708-714 (2002).
67. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 23(3), 144-150 (2002).
68. Chattopadhyay S, Bhattacharyya S, Saha B et al. Tumor-shed prostaglandin E2 impairs IL2Rgc-signaling to inhibit CD4 T cell survival: Regulation by theaflavins. PLoS ONE 4, e7382 (2009).
69. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24(8), 792-799 (2002).
70. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev. 24(1), 95-105 (2005).
71. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int. J. Cancer 67(3), 333-338 (1996).
72. Whiteside TL. Down-regulation of z-chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol. Immunother. 53(10), 865-878 (2004).
73. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the z chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 58(23), 5344-5347 (1998).
74. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: Clinical and immunogenetic consequences. Clin. Cancer Res. 6(7), 2794-2802 (2000).
75. Meissner M, Whiteside TL, van Kuik- Romein P et al. Loss of IFN-g inducibility of the MHC class II antigen processing pathway in head and neck cancer: Evidence for post-transcriptional as well as epigenetic regulation. Br. J. Dermatol. 158(5), 930-940 (2008).
76. Bandoh N, Ogino T, Katayama A et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol. Rep. 23(4), 933-939 (2010).
77. Kalyankrishna S, Grandis Jr. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 24(17), 2666-2672 (2006).
78. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579-3584 (1993).
79. Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin. Invest. Drugs 19(6), 709-722 (2010).
80. Bier H, Hoffmann T, Hauser U et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 47(6), 519-524 (2001).
81. Modjtahedi H, Hickish T, Nicolson M et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 73(2), 228-235 (1996).
82. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
83. Wirth LJ, Allen AM, Posner MR et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann. Oncol. 21(2), 342-347 (2010).
84. Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat. Rev. Drug Discov. 5, 987-988 (2006).
85. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
86. Kundu SK, Nestor M. Targeted therapy in head and neck cancer. Tumour Biol. 33(3), 707-721 (2012).
87. Seiwert TY, Haraf DJ, Cohen EE et al. Phase I study of bevacizumab added to fluorouracil-and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J. Clin. Oncol. 26(10), 1732-1741 (2008).
88. Lee NY, Zhang Q, Pfister DG et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (radiation therapy oncology group 0615): A Phase 2 multi-institutional trial. Lancet Oncol. 13(2), 172-180 (2012).
89. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21(2), 233-240 (2009).
90. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol. 2010, 689171 (2010).
91. Pauli C, Munz M, Kieu C et al. Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. Cancer Lett. 193(1), 25-32 (2003).
92. Riechelmann H, Wiesneth M, Schauwecker P et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Cancer Immunol. Immunother. 56(9), 1397-1406 (2007).
93. Molling JW, Langius JA, Langendijk JA et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25(7), 862-868 (2007).
94. Schneiders FL, de Bruin RC, van den Eertwegh AJ et al. Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: Updated analysis with 10-year follow-up. J. Clin. Oncol. 30(5), 567-570 (2012).
95. Yamasaki K, Horiguchi S, Kurosaki M et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 138(3), 255-265 (2011).
96. Okamoto Y, Fujikawa A, Kurosaki M et al. Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy. Adv. Otorhinolaryngol. 72, 149-152 (2011).
97. Kurosaki M, Horiguchi S, Yamasaki K et al. Migration and immunological reaction after the administration of aGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol. Immunother. 60(2), 207-215 (2011).
98. Jorritsma A, Gomez-Eerland R, Dokter M et al. Selecting highly affine and well-expressed T cell receptors (TCR) for gene therapy of melanoma. Blood 110(10), 3564-3572 (2007).
99. Scholten KB, Kramer D, Kueter EW et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119(2), 135-145 (2006).
100. Scholten KB, Turksma AW, Ruizendaal JJ et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J. Transl. Med. 9, 147 (2011).
101. Scholten KB, Ruizendaal JJ, Graf M et al. Promiscuous behavior of HPV16E6 specific T cell receptor b chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification. Cell. Oncol. 32(1-2), 43-56 (2010).
102. Scholten KB, Schreurs MW, Ruizendaal JJ et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin. Immunol. 114(2), 119-129 (2005).
103. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J. Immunol. 171(6), 2912-2921 (2003).
104. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7(10), 790-802 (2007).
105. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180(1), 83-93 (1994).
106. Figdor CG, de Vries I, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat. Med. 10(5), 475-480 (2004).
107. Bontkes HJ, Ruizendaal JJ, Kramer D et al. Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature DC. J. Immunother. 29(2), 188-200 (2006).
108. Bontkes HJ, de Gruijl TD, Schuurhuis GJ, Scheper RJ, Meijer CJ, Hooijberg E. Expansion of dendritic cell precursors from human CD34+ progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J. Leukoc. Biol. 72(2), 321-329 (2002).
109. Santegoets SJ, Bontkes HJ, Stam AG et al. Inducing antitumor T cell immunity: Comparative functional analysis of interstitial versus Langerhans DC in a human cell line model. J. Immunol. 180(7), 4540-4549 (2008).
110. Santegoets SJ, Schreurs MW, Masterson AJ et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic DC derived from the human MUTZ-3 cell line. Cancer Immunol. Immunother. 55(12), 1480-1490 (2006).
111. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human DC ingesting apoptotic tumor cells. Cancer Res. 60(13), 3542-3549 (2000).
112. Gholamin M, Moaven O, Farshchian M et al. Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded DC in esophageal squamous cell carcinoma: Preliminary step for DC vaccine design. BMC Cancer 10, 261 (2010).
113. Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E. Tumor associated antigen and IL-12 mRNA transfected DC enhance effector function of natural killer cells and antigen specific T-cells. Clin. Immunol. 127(3), 375-384 (2008).
114. Bontkes HJ, Kramer D, Ruizendaal JJ et al. Dendritic cells transfected with IL-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 14(4), 366-375 (2007).
115. Hoffmann TK, Nakano K, Elder EM et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: Implications for immunoselection of epitope loss variants. J. Immunol. 165(10), 5938-5944 (2000).
116. Clayman GL, Young G, Taylor DL, Savage HE, Lavedan P, Schantz SP. Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with IL-2 and IFNa. Ann. Otol. Rhinol. Laryngol. 101(11), 909-915 (1992).
117. Dadian G, Riches PG, Henderson DC et al. Immune changes in peripheral blood resulting from locally directed IL-2 therapy in squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol. 29B(1), 29-34 (1993).
118. De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic IL-2: Clinical and pathologic correlations. J. Immunother. Emphasis Tumor Immunol. 19(2), 125-133 (1996).
119. Mantovani G, Bianchi A, Curreli L et al. Neo-adjuvant chemotherapy ± immunotherapy with s.c. IL 2 in advanced squamous cell carcinoma of the head and neck: A pilot study. Biotherapy 8(2), 91-98 (1994).
120. Mantovani G, Gebbia V, Airoldi M et al. Neo-adjuvant chemo-(immuno-) therapy of advanced squamous-cell head and neck carcinoma: A multicenter, Phase III, randomized study comparing cisplatin + 5-fluorouracil with cisplatin + 5-fluorouracil + recombinant IL 2. Cancer Immunol. Immunother. 47(3), 149-156 (1998).
121. Recchia F, Candeloro G, Di SM et al. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Immunother. 31(4), 413-419 (2008).
122. Timar J, Ladanyi A, Forster-Horvath C et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/ CD8 ratio and tumor microenvironment: A multicenter Phase II clinical trial. J. Clin. Oncol. 23(15), 3421-3432 (2005).
123. Meneses A, Verastegui E, Barrera JL, Zinser J, de la GJ, Hadden JW. Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (iroquois homeobox protein-2, IRX-2) prior to surgery. Arch. Pathol. Lab. Med. 122(5), 447-454 (1998).
124. Freeman SM, Franco JL, Kenady DE et al. A Phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am. J. Clin. Oncol. 34(2), 173-178 (2011).
125. Hadden J, Verastegui E, Barrera JL et al. A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck. Int. Immunopharmacol. 3(8), 1073-1081 (2003).
126. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Combination immunotherapy of squamous cell carcinoma of the head and neck: A Phase 2 trial. Arch. Otolaryngol. Head Neck Surg. 126(3), 345-351 (2000).
127. Berinstein NL, Wolf GT, Naylor PH et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol. Immunother. 61(6), 771-782 (2011).
128. Schutt C, Bumm K, Mirandola L et al. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int. Rev. Immunol. 31(1), 22-42 (2012).
129. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: Current and future considerations. J. Oncol. 2009, 346345 (2009).
130. Maio M. Melanoma as a model tumour for immuno-oncology. Ann. Oncol. 23(Suppl. 8), 10-14 (2012).
131. Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB, Whiteside TL. Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck 31(6), 773-781 (2009).
132. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(21), 6301-6311 (2007).
133. Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual. Life Outcomes 10, 66 (2012).
134. van den Eertwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509-517 (2012).
135. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat. Rev. Cancer 11(11), 805-812 (2011).
136. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
137. Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O, Hashimoto K. Tumor-infiltrating lymphocytes, particularly the balance between CD8+ T cells and CCR4+ regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 109(5), 744-752 (2010).
138. Badoual C, Hans S, Rodriguez J et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12(2), 465-472 (2006).
139. Wansom D, Light E, Thomas D et al. Infiltrating lymphocytes and human papillomavirus-16-associated oropharyngeal cancer. Laryngoscope 122(1), 121-127 (2012).
140. Wansom D, Light E, Worden F et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch. Otolaryngol. Head Neck Surg. 136(12), 1267-1273 (2010).
141. Turksma AW, Bontkes HJ, van den Heuvel H et al. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis. doi:10.1111/odi.12037 (2012) (Epub ahead of print).
142. Heusinkveld M, Goedemans R, Briet RJ et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int. J. Cancer 131(2), e74-e85 (2012).
143. Szarewski A. Cervarix(R): A bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Rev. Vaccines 11(6), 645-657 (2012).
144. Goldstone SE, Vuocolo S. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Expert Rev. Vaccines 11, 395-406 (2012).
145. Chan AT. Nasopharyngeal carcinoma. Ann. Oncol. 21(Suppl. 7), 308-312 (2010).
146. Lin CL, Lo WF, Lee TH et al. Immunization with EBV peptide-pulsed DC induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62(23), 6952-6958 (2002).
147. Wildeman MA, Novalic Z, Verkuijlen SA et al. Cytolytic virus activation therapy for EpsteinYBarr virus driven tumours. Clin. Cancer Res. 18(18), 5061-5070 (2012).